Safety of Hydroxychloroquine in COVID-19

1 2	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
2 3 4 5 6 7 8 9 10 11	Sarah M Lofgren, <sup>1</sup> Melanie R Nicol, <sup>1</sup> Ananta S Bangdiwala, <sup>1</sup> Katelyn A Pastick, <sup>1</sup> Elizabeth C Okafor, <sup>1</sup> Caleb P Skipper, <sup>1</sup> Matthew F Pullen, <sup>1</sup> Nicole W Engen, <sup>1</sup> Mahsa Abassi, <sup>1</sup> Darlisha A Williams, <sup>1</sup> Alanna A Nascene, <sup>1</sup> Margaret L Axelrod BSc, <sup>2</sup> Sylvain A Lother, <sup>3</sup> Lauren J MacKenzie, <sup>3</sup> Glen Drobot, <sup>3</sup> Nicole Marten <sup>4</sup> , Matthew P Cheng, <sup>6,7</sup> Ryan Zarychanski, <sup>3,4</sup> Ilan S Schwartz, <sup>5</sup> Michael Silverman, <sup>8</sup> Zain Chagla, <sup>9</sup> Lauren E Kelly, <sup>4</sup> Emily G McDonald, <sup>6,7</sup> Todd C Lee, <sup>6,7</sup> Kathy H Hullsiek, <sup>1</sup> David R. Boulware, <sup>1</sup> Radha Rajasingham. <sup>1</sup>
12 13 14 15 16 17 18 19 20 21 22 23 24	<ol> <li>University of Minnesota, Minneapolis, Minnesota</li> <li>Vanderbilt University Medical Center, Nashville, Tennessee</li> <li>Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba</li> <li>George &amp; Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba</li> <li>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta</li> <li>Research Institute of the McGill University Health Centre, Montreal, Quebec</li> <li>Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec</li> <li>Lawson Research Institute, St. Joseph's Healthcare Center, London, Ontario</li> <li>McMaster University, Hamilton, Ontario</li> </ol>
25 26 27 28 29 30 31 32 33 34 35 36	Keywords: Hydroxychloroquine, Covid-19, Safety, SARS-Cov2, Side-effects Word Count: Total: 2860; Abstract 243 Corresponding author: Dr. Sarah Lofgren, 689 23rd Avenue S.E., Minneapolis, MN 55455; Phone 612-624-4171; Lofg0020@umn.edu Dr. Rajasingham is the Alternative Corresponding Author: radha@umn.edu Clinicaltrials.gov Identifier:
37	NCT04308668 for post-exposure prophylaxis and early treatment trials.
38 39 40 41	NCT04328467 for pre-exposure prophylaxis trial. Short Summary

Safety of Hydroxychloroquine in COVID-19

- 42 Data from three randomized clinical trials using hydroxychloroquine for the prevention and
- 43 treatment of COVID-19 did not suggest significant safety concerns. Gastrointestinal side effects
- 44 were common but arrhythmias were rare. There were no sudden deaths in any trial.

Safety of Hydroxychloroguine in COVID-19

## 46 Abstract

47 **Introduction**: Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in

48 combination with azithromycin, has raised safety concerns. Here, we report safety data from

49 three outpatient randomized clinical trials.

50 **Methods:** We conducted three randomized, double-blind, placebo-controlled trials investigating

51 hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early

52 treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine.

53 We collected side effects and serious adverse events. We report descriptive analyses of our

54 findings.

55 Results: We enrolled 2,795 participants. The median age of research participants was 40 (IQR

56 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324

57 (84%) participants reported side effect data, and 638 (27%) reported at least one medication

side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once

59 weekly hydroxychloroquine compared to 19% with placebo. The most common side effects

60 were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs.

61 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice

62 weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial

arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deathsoccurred.

65 Conclusion: Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side
66 effects were common but mild with the use of hydroxychloroquine, while serious side effects
67 were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can
68 safely investigate whether hydroxychloroquine is efficacious for COVID-19.

69

Safety of Hydroxychloroquine in COVID-19

## 70 Introduction:

71 Hydroxychloroquine has in vitro antiviral activity against Severe Acute Respiratory 72 Syndrome-related coronavirus 2 (SARS-CoV-2).[1, 2] While in vitro data suggest that both 73 chloroquine and hydroxychloroquine have activity against SARS-CoV-2 replication, the latter is 74 generally considered less toxic and better tolerated. However, clinical data to date demonstrate 75 no conclusive efficacy of hydroxychloroguine for the treatment or prevention of COVID-19.[3-5] 76 Both chloroquine and hydroxychloroquine impede SARS-CoV-2 replication.[2] Several 77 randomized placebo-controlled clinical trials are underway to evaluate hydroxychloroguine's 78 safety and efficacy in the prevention and treatment of COVID-19 in both inpatient and outpatient 79 populations.[6] 80 In late March 2020, hydroxychloroguine had substantial positive coverage in the media. 81 However, the tide rapidly turned due to concerted efforts to inform physicians and patients about 82 the potential risks of taking the drug outside of clinical trial settings.[7] Several inpatient 83 treatment studies then went on to show increased cardiac side effects with hydroxychloroguine 84 and azithromycin.[8, 9] On April 24th, 2020, the U.S Food and Drug Administration (FDA) issued 85 a caution against chloroquine and hydroxychloroquine in the treatment of COVID-19 outside of 86 hospital settings or clinical trials.[10] The FDA stated, "Hydroxychloroguine and chloroguine can 87 cause abnormal heart rhythms such as QT interval prolongation and...ventricular tachycardia." 88 The FDA noted that QT prolongation was more common among persons receiving azithromycin 89 and those with prior heart problems or kidney disease. 90 Hydroxychloroguine nonetheless has a 65-year track record of safety when prescribed at 91 recommended doses in populations with normal liver and kidney function, and without pre-92 existing cardiac arrhythmias.[11] In the medical specialties of tropical medicine and

rheumatology, chloroquine and hydroxychloroquine have routinely been prescribed without

- 94 baseline laboratory testing or EKG monitoring. Whether these tests should be performed in the
- 95 setting of hydroxychloroquine for COVID-19 is controversial. As it stands, a number of ongoing

#### Safety of Hydroxychloroquine in COVID-19

96	clinical trials have been paused or halted by regulatory authorities over concerns related to the
97	potential for QT prolongation. Importantly, these safety concerns have risen from reports of
98	hydroxychloroquine use in hospitalized patients, who are more likely to have severe infections,
99	significant comorbidities and be on multiple concurrent medications.[12]
100	There are some features of the SARS-CoV-2 virus which may predispose individuals
101	with COVID-19 to be more likely to have complications from drugs that prolong the QT than
102	healthy individuals. SARS-CoV-2 itself can enter cardiomyocytes and may cause direct cardiac
103	injury.[13-15] Multiple reports of increased arrhythmias in individuals with COVID-19 without
104	other cause, suggest SARS-CoV-2 itself may cause arrhythmias.[15] Alternatively, elevated
105	cytokines directly or in concert with cardiomyocyte damage, may predispose to arrhythmias.[16]
106	Additionally, COVID-19 is associated with significant electrolyte imbalances, including sodium,
107	potassium, and calcium as well as renal failure, each of which also predispose individuals to
108	arrhythmias.[15, 17] Therefore testing the safety of hydroxychloroquine in individuals with
109	COVID-19 specifically is valuable.
110	The safety of hydroxychloroquine use for COVID-19 in outpatients has not been
111	established, but is believed to be less risky in outpatients than inpatients.[18] To address
112	current knowledge gaps regarding the safety and tolerability of hydroxychloroquine in the
113	outpatient prevention and treatment of COVID-19, and to inform its future usage in the setting of
114	clinical trials, we present the safety data from three randomized placebo-controlled clinical trials
115	of hydroxychloroquine in North America.
116	

116

## 117 Methods:

118 Study Design:

We conducted three randomized, double-blind, placebo-controlled trials investigating
hydroxychloroquine as prophylaxis and treatment for COVID-19 disease. The first two trials

Safety of Hydroxychloroquine in COVID-19

121	evaluated: 1) post-exposure prophylaxis (PEP); 2) preemptive early treatment (PET),
122	(Clinicaltrials.gov Identifier: NCT04308668).[3, 19] Trial enrollment began on March 17, 2020,
123	concluded on May 6, and follow up was completed on May 20, 2020. The third trial assessed
124	pre-exposure prophylaxis (PREP) for COVID-19 (ClinicalTrials.gov Identifier: NCT04328467).
125	Enrollment for this third trial began April 6 and ended May 26, 2020, with follow-up concluding
126	on July 13, 2020.
127	In each of these trials, participants were randomized to receive placebo or hydroxychloroquine.
128	The PEP trial required participants to have a known exposure to a lab-confirmed COVID-19
129	case within four days either as a household contact or as a healthcare worker or first responder.
130	The PET trial enrolled persons with COVID-19 symptoms of four or fewer days duration and
131	either lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of
132	symptom onset. The PREP required persons to be high-risk healthcare workers or first
133	responders with ongoing occupational exposure to COVID-19.
134	Hydroxychloroquine dosing for both the PEP and PET trials was 800mg load dosing,
135	followed by 600mg in 6-8 hours, and then 600mg daily for five days in total. Participants were
136	instructed to split their follow-up dosing in the event of gastrointestinal upset. In designing the
137	trials, investigators chose doses within the existing FDA-approved dosing range that were
138	modeled to achieve therapeutic concentrations from day 1 through 10.[20] Hydroxychloroquine
139	dosing for PREP was dosed at 400 mg orally once, followed by 400mg 6 to 8 hours later,
140	thereafter 400mg weekly or twice weekly for the duration of follow-up, up to 12 weeks. The
141	placebo was dosed similarly.
142	
143	Study Participants:
144	Participants were enrolled in the three trials via internet-based surveys throughout the

145 United States and selected Canadian provinces. Full details are online (Clinicaltrials.gov
146 Identifier: NCT04308668, NCT04328467).[3] Participants were excluded if they were <18 years</li>

#### Safety of Hydroxychloroquine in COVID-19

147 old, had an allergy to hydroxychloroguine, retinal eye disease, known glucose-6 phosphate dehydrogenase (G6PD) deficiency, known chronic kidney disease, stage 4 or 5 or receiving 148 149 dialysis, known porphyria, weight <40 kg, known QT prolongation, or receiving chemotherapy. 150 Current use of hydroxychloroquine, azithromycin, or cardiac arrhythmia medicines (flecainide, amiodarone, digoxin, procainamide, propafenone, or sotalol) were also exclusion criteria. On 151 152 April 20, 2020, the FDA required additional exclusions of structural or ischemic heart disease 153 and personal or family history of cardiac QT prolongation, and medications that prolong the QTc 154 interval.

155 Health Canada mandated additional exclusions for Canadian participants. Women who 156 were pregnant or breastfeeding were excluded, as were patients with: severe diarrhea or 157 vomiting; known cirrhosis with a history of encephalopathy or ascites; known prolonged cardiac 158 QTc interval, history of ventricular arrhythmia or history of sudden cardiac death; patients taking 159 additional medicines that had a high risk of prolonging the electrocardiogram QTc interval in 160 conjunction with hydroxychloroquine. The Institutional Review Board (IRB) in Ontario also 161 mandated that a physician perform a complete review of medications for participants above age 162 65, to exclude those with important drug-drug interactions.

Participants in the PEP and PET trials completed follow-up email surveys on Days 1, 3, 5, 10, and 14, whereas participants in the PREP trial completed weekly follow-up surveys. Surveys obtained self-report of study drug adherence, side effects, new COVID-19 symptoms, new COVID-19 testing, and hospitalization. For participants who stopped their study drug due to side effects or other reasons, we encouraged them to continue observational follow-up and completion of self-report surveys.

169

170

171 Statistical Analysis:

Safety of Hydroxychloroquine in COVID-19

The analysis presented is primarily descriptive, summarizing the frequency of reported
medication side effects and medication-related serious adverse events, such as hospitalization,
life-threatening events, or deaths. With follow-up ongoing for the PREP study at the time of
publication, data through June 25, 2020, are included in this analysis.
Patient Consent Statement:
The participant's written consent was obtained. IRB approval of the design of the work
occurred at McGill University, Clinical Trials Ontario, University of Manitoba, and University of
Alberta, and the University of Minnesota.
Results:
A total of 2795 individuals were enrolled into the three trials. The combined median age
was 40 years (interquartile range [IQR] 34-49) and 51% were women. The median weight was
79 kg (IQR 66-91). The majority of participants (74%) were healthcare workers and first
responders. Approximately 66% of the participants were taking no chronic medications, and
59% had no chronic medical conditions. Demographic data are displayed in <b>Table 1</b> .
Post-exposure prophylaxis and early treatment trials
Of 1312 (n=821 PEP; n=491 PET) participants randomized, 87% (n=1139) started study
drug and completed follow-up surveys. Of 130 participants who started drug but did not
complete follow up, vital status was obtained for 32% (42/130), and all were alive. For the
remainder, we performed an internet search for death records and found none.

#### Safety of Hydroxychloroquine in COVID-19

197 Of 1139 who started study drug and reported side effect data, 29% reported one or 198 more side effects, with more side effects reported among those on hydroxychloroquine (40%) 199 versus placebo (18%) (Table 2). The most common side effects reported were upset stomach 200 or nausea (25% on hydroxychloroquine versus 9% on placebo), followed by vomiting, diarrhea, 201 or other GI symptoms (23% on hydroxychloroquine versus 6% on placebo), and neurologic 202 reactions, such as lightheadedness or dizziness (7% on hydroxychloroguine versus 5% on 203 placebo). Self-reported allergic reactions, occurred in 7 participants (6 on hydroxychloroquine 204 and 1 on placebo). There were no reported episodes of arrhythmias or sudden cardiac death. 205 Only 46 participants (4%) from the PEP and PET trials reported that they stopped the 5-206 day treatment course due to side effects. The distribution of side effects was similar among both 207 trials. No serious adverse events, resulting in hospitalization, attributable to medication side 208 effects were reported. 209 Since gastrointestinal issues are known to occur in COVID-19, we compared side effects

between the placebo groups in the PEP group versus those who had COVID-19 in the PET group. We did not identify a statistical difference in the incidence of nausea / upset stomach reports in those with COVID-19 versus those exposed (11% vs. 8%, p=0.12). Similarly, the incidence of diarrhea, abdominal pain, vomiting, or other gastrointestinal issues did not differ between those with COVID-19 versus those exposed (7% vs. 4%, p=0.14). The risk of having any side effects did not differ by sex, age group, weight, or if one was a healthcare worker or not (**Table 3**).

217

## 218 Pre-exposure prophylaxis trial

Interim data June 25, 2020, demonstrated that of 1483 randomized, 1402 had follow up
data. Overall, 409 (29%) individuals experienced at least one side effect during the study (**Table**4). Side effects were higher for those receiving hydroxychloroquine: 36% of those on twiceweekly dosing, 31% on weekly dosing, and 21% on placebo reported at least one side effect.

#### Safety of Hydroxychloroquine in COVID-19

223	Similar to the other trials, the most common side effects reported were upset stomach or
224	nausea (18% on hydroxychloroquine twice weekly, 16% on hydroxychloroquine weekly, and
225	12% on placebo), followed by vomiting, diarrhea, or other GI symptoms (16% on
226	hydroxychloroquine twice weekly, 12% on hydroxychloroquine weekly, and 6% on placebo).
227	Two participants experienced atrial arrhythmias. One participant on placebo was hospitalized
228	twice with atrial fibrillation. Another participant on hydroxychloroquine twice weekly was
229	hospitalized after a syncopal event and was found to have a supraventricular tachycardia. No
230	ventricular arrhythmias were reported.
231	In total, across the three cohorts, 25 individuals have been hospitalized through June 25,
232	2020 (1% incidence). The PEP trial had two hospitalizations, one in each arm and no deaths.
233	The PET trial had 14 hospitalizations and two deaths. With hydroxychloroquine, 4
234	hospitalizations and 1 non-hospitalized death occurred. With placebo, 10 hospitalizations
235	occurred with one hospitalized death. Two hospitalizations were for non-COVID-19, non-study
236	medication related reasons, while the remaining 12 hospitalizations were due to COVID-19.
237	Nine individuals were hospitalized from the PREP study, one for COVID-19, two for arrhythmias
238	(one on hydroxychloroquine twice a day and one on placebo), and the other seven
239	hospitalizations were for non-study related reasons. No sudden unexplained deaths have been
240	reported in any of the three trials. Full details are in <b>Supplemental Table 1</b> .
241	

241

## 242 Discussion:

Among 2464 participants reporting on side effects from 3 randomized clinical trials investigating the efficacy of hydroxychloroquine in outpatient COVID-19 prevention and treatment, 27% reported at least one medication-related side effect. We captured one episode of supraventricular tachyarrhythmia with syncope in an individual on hydroxychloroquine and two episodes of atrial fibrillation in one individual on placebo. Whether hydroxychloroquine was

## Safety of Hydroxychloroquine in COVID-19

248	responsible or contributed to the development of the supraventricular tachycardia is unclear.
249	Hydroxychloroquine prolongs the QT interval and therefore is associated with an increased risk
250	of ventricular arrhythmias, not atrial arrhythmias. Regardless, atrial arrhythmias were rare in
251	both arms, and there were no episodes of ventricular arrhythmia or sudden death in
252	approximately 50,000 patient-days of cumulative exposure.
253	As expected, the most common side effects were nausea and gastrointestinal upset. In
254	addition to hydroxychloroquine, COVID-19 is also known to cause gastrointestinal upset.
255	However, when we compared the rate of gastrointestinal upset among those receiving placebo
256	in the post-exposure prophylaxis cohort versus those in the symptomatic cohort, reported
257	gastrointestinal side effects were not significantly more frequent. Most participants regarded
258	gastrointestinal upset upset as tolerable and completed the course of medication.
259	Medications causing QT prolongation are feared due to the risk of inducing ventricular
260	arrhythmias, yet reports of arrhythmias due to hydroxychloroquine use are most often reported
261	in the setting of co-ingestion, chronic use, or overdose.[21-23] The FDA does not recommend
262	hydroxychloroquine be used with other agents that prolong the QTc,[11] such as
263	azithromycin.[24] In 2017, the World Health Organization (WHO) reported that there has never
264	been a reported sudden cardiac death attributable to chloroquine when prescribed at malaria
265	treatment doses.[25] Despite the long history of chloroquine/hydroxychloroquine for malaria
266	treatment and rheumatological diseases such as lupus, there have been increasing concerns
267	around side effects in patients with COVID-19, especially related to arrhythmias.[26, 27] The
268	FDA has now changed their emergency use authorization recommendation for
269	hydroxychloroquine in COVID-19 treatment and prevention for this reason, among many others.
270	[10]
271	For context, a perspective on dosing is needed to understand potential risks with
272	chloroquine/hydroxychloroquine. Decades of safety data are available for the standard doses of
272	oblerequipe used for maleria prophylovia (500 mg [200 mg oblerequipe base] weekly) and

273 chloroquine used for malaria prophylaxis (500 mg [300 mg chloroquine base] weekly) and

#### Safety of Hydroxychloroquine in COVID-19

274	malaria treatment (2.5 g [1.5g chloroquine base] total over three days). Cardiac conduction
275	alterations were mostly seen when using much higher doses in hospitalized patients with
276	COVID-19 (12 g chloroquine base over 10 days).[9] The cumulative dose of
277	hydroxychloroquine-base used in our PEP and PET trials is 3.8 g (2.9 g base) total over 5 days.
278	This is in line with established safe dosing strategies and below the doses shown to cause
279	harmful effects.[28, 29] The Outcomes Related to COVID-19 Treated with Hydroxychloroquine
280	among In-patients with Symptomatic Disease (ORCID) trial used 400 mg twice on day one
281	followed by 200 mg twice daily for five days total (ClinicalTrials.gov Identifier: NCT04332991).
282	They enrolled 479 individuals and also found no significant safety concerns at that dose.[30]
283	Similarly, the RECOVERY trial used 2.4 g (1.86 g base) in four divided doses over 24 hours,
284	followed by 800 mg (620 mg base) for an additional 9 days or until discharge and they reported
285	no significant safety concerns in 11,000 hospitalized patients with COVID-19 randomized to
286	hydroxychloroquine or placebo.[31]

287 Our trials additionally excluded participants taking azithromycin and other QT-prolonging 288 drugs to enhance safety further. Other risk factors for QT prolongation, such as hypokalemia or 289 hypomagnesemia, are uncommon in outpatients.[32, 33] Mercuro, et al. found QTc prolongation 290 at 2.4 g courses of hydroxychloroquine over five days, but only clinically concerning side effects 291 when combined with azithromycin and side effects were more common among those already on 292 loop diuretics.[8] Our data showed one potential cardiac complication (atrial arrhythmia) in one 293 individual on hydroxychloroquine and one on placebo. Our potential rate of atrial arrhythmias 294 due to hydroxychloroquine is less than one in 1000. Many commonly used drugs, including 295 antibacterial, antifungal, and other antimalarial drugs, are known to prolong the QT, thereby 296 having a rare occurrence of arrhythmias.[34] The risk of QT prolongation has not precluded the 297 use of drugs such as ciprofloxacin or fluconazole in most patients, but has required clinicians 298 exercise caution.

#### Safety of Hydroxychloroquine in COVID-19

299 Despite our rational design of these clinical trials, several limitations still exist. A 300 significant limitation of our studies is related to their pragmatic nature, which relied on accurate 301 self-reporting. We did not prospectively record or evaluate for laboratory abnormalities or QTc 302 changes. While we have outcome data on 93% of participants who have completed the studies, 303 it is possible, given the passive nature of self-reported follow-up, that those lost-to-follow-up 304 may have had an adverse event that was not reported to our study team or their designated 305 emergency contacts. Additionally, our cohorts are relatively young, with a median age of 40. 306 They had few comorbidities and were on few medications. They were also predominantly 307 healthcare workers, comprising a population of individuals with high health literacy. All these 308 factors make our outpatient research participants healthier than most hospitalized patients in 309 North America. Finally, our study exclusively included outpatients. Patients admitted to hospital 310 are generally older and have more comorbidities. They also are more likely to have cardiac 311 complications of COVID-19 and thus may be more susceptible to develop adverse effects from 312 hydroxychloroquine.

313

#### 314 Conclusion

315 While efforts towards the development of a vaccine continue, agents that can prevent 316 and treat COVID-19 are important. There is still equipoise concerning the potential efficacy of 317 hydroxychloroguine as an effective agent against COVID-19: thus, timely completion of 318 randomized placebo-controlled clinical trials is essential. Thus, large scale clinical trials to 319 carefully evaluate the limited potential therapeutics that have been identified and perhaps even 320 to replicate results of completed trials are imperative to our public health response. Ongoing 321 clinical trials can safely continue with research participants and regulatory bodies reassured as 322 to the general safety of hydroxychloroguine when using appropriate exclusion criteria.

323

Safety of Hydroxychloroquine in COVID-19

324 Conflicts of Interest: Authors are actively involved in clinical trials to prevent or treat COVID-

19. No author has a financial interest in remote EKG monitoring products or services.

- 326
- 327

## 328 Acknowledgments

329 This work was supported by Jan and David Baszucki, Steve Kirsch, the Alliance of 330 Minnesota Chinese Organizations, the Minnesota Chinese Chamber of Commerce, and the 331 University of Minnesota. Personnel was supported through the Doris Duke Charitable 332 Foundation through a grant supporting the Doris Duke International Clinical Research Fellows 333 Program at the University of Minnesota. Katelyn Pastick and Elizabeth Okafor are Doris Duke 334 International Clinical Research Fellows. Sarah Lofgren is supported by the National Institute of 335 Mental Health (K23MH121220), Caleb Skipper is supported by the Fogarty International Center (D43TW009345). Drs. Melanie Nicol, Radha Rajasingham, and Matthew Pullen are supported 336 337 by the National Institute of Allergy and Infectious Disease (K08Al134262, K23Al138851, 338 T32AI055433). Margaret Axelrod is supported by NIH T32GM007347 and F30CA236157. Drs. 339 Lee and McDonald receive salary support from the Fonds de recherche du Québec – Santé. 340 Canadian funding was received from various sources. In Quebec, funds were received from the 341 Clinical Practice Assessment Unit of the McGill University Health Centre and the McGill 342 Interdisciplinary Initiative in Infection and Immunity's Emergency COVID-19 Research Funding. 343 In Manitoba, research support was provided from the Manitoba Medical Service Foundation. In 344 Alberta, support was provided by Northern Alberta Clinical Trials and Research Centre. In 345 Ontario. support was provided by the Research Institute of St. Joseph's Hamilton, the St 346 Joseph's Hospital Foundation in London, and Bridge to Health Medical and Dental. Purolator 347 Canada provided in-kind courier support for Canadian sites participating in the post-exposure 348 and early treatment trials. Apotex Pharmaceuticals Canada provided a donation of some of the 349 hydroxychloroquine tablets used. Rising Pharmaceutical donated some of the medicine for U.S.

Safety of Hydroxychloroquine in COVID-19

- 350 trials. COVID-19 Emergency Supplement funding was requested from the National Institutes of
- 351 Health for each of the three trials.
- 352
- 353
- 354 **References:**
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J **2005**; 2: 69.
- Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized
   Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory
   Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official
   publication of the Infectious Diseases Society of America **2020**.
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of
   Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. The New England
   journal of medicine **2020**.
- Pastick KA, Okafor EC, Wang F, et al. Review: Hydroxychloroquine and Chloroquine for
   Treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis **2020**; 7(4): ofaa130.
- RECOVERY Trial. Statement from the Chief Investigators of the Randomised Evaluation
   of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020.
   Available at: <u>https://www.recoverytrial.net/results</u>. Accessed 5 June 2020.
- Cheng MP, Lee TC, Tan DHS, Murthy S. Generating randomized trial evidence to
   optimize treatment in the COVID-19 pandemic. CMAJ : Canadian Medical Association
   journal = journal de l'Association medicale canadienne **2020**; 192(15): E405-E7.
- Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and
   azithromycin in the management of SARS-CoV-2 infection. CMAJ : Canadian Medical
   Association journal = journal de l'Association medicale canadienne 2020; 192(17): E450 E3.
- Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With
   Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among
   Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA
   Cardiol 2020.
- Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine
   Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute
   Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open
   2020; 3(4): e208857-e.
- FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of
   the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at:

Safety of Hydroxychloroquine in COVID-19

386 387		https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use- hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or.
388 389 390	11.	Hydroxychloroquine FDA Package Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pd f. Accessed May 1, 2020.
391 392 393	12.	Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. Journal of the American Geriatrics Society <b>2020</b> .
394 395 396	13.	Guo J, Wei X, Li Q, et al. Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. J Cell Physiol <b>2020</b> .
397 398	14.	Sharma A, Garcia G, Arumugaswami V, Svendsen CN. Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. bioRxiv <b>2020</b> .
399 400 401	15.	Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol <b>2020</b> ; 178: 114114.
402 403	16.	Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ <b>2020</b> .
404 405	17.	Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem <b>2020</b> ; 57(3): 262-5.
406 407	18.	Sacher F, Fauchier L, Boveda S, et al. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. Arch Cardiovasc Dis <b>2020</b> ; 113(5): 293-6.
408 409 410 411	19.	Lother SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian journal of anaesthesia = Journal canadien d'anesthesie <b>2020</b> .
412 413 414	20.	Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: The desperate search for effectiveness. Clinical pharmacology and therapeutics <b>2020</b> .
415 416	21.	Cheng WF, Kao NC, Tsao KH, Chen CJ, Sun TJ, Wang YC. The Inhibition of Immunologic Response by Chloroquine. Chin Med J <b>1964</b> ; 83: 531-5.
417 418	22.	Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med <b>2020</b> .
419 420 421 422	23.	Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT- interval prolongation in a patient with systemic lupus erythematosus. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases <b>2013</b> ; 19(5): 286-8.

Safety of Hydroxychloroquine in COVID-19

- 423 24. Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin,
  424 cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory
  425 issues: A narrative review based on the study of case reports. Ther Adv Infect Dis 2013;
  426 1(5): 155-65.
- 427 25. The cardiotoxicity of antimalarials. In: Malaria Policy Advisory Committee Meeting.
  428 Geneva, Switzerland: World Health Organization (WHO), 2017:1-49.
- 429 26. Glenza J. Brazilian chloroquine study halted after high dose proved lethal for some patients. Available at: <u>https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil</u>.
- 432 27. Shaw ML. Caution Strongly Recommended When Using Chloroquine,
   433 Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19. Available at:
   434 <u>https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-</u>
   435 chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19.
- 436 28. Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity.
  437 Rheumatology (Oxford) **2016**; 55(6): 957-67.
- 438 29. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response
  439 relationships in patients with rheumatoid arthritis. Arthritis Rheum **2002**; 46(6): 1460-9.
- 440 30. Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19.

441 31. Horby P LM. Correspondence to All RECOVERY Principal Investigators.
442 <u>https://www.recoverytrial.net/files/professional-</u>
443 <u>downloads/recovery\_noticetoinvestigators\_2020-05-24\_1422.pdf</u>: RECOVERY Central
444 Coordinating Office, **2020**:2.

- 32. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions
  on QTc Interval in Exploratory COVID-19 Treatment. Heart Rhythm 2020.
- 33. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on Minimizing Risk of Drug-Induced
  Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian
  Heart Rhythm Society. The Canadian journal of cardiology **2020**; 36(6): 948-51.
- 450 34. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart **2003**; 451 89(11): 1363-72.
- 452
- 453
- 454

Safety of Hydroxychloroquine in COVID-19

## Table 1. Baseline Demographics for all three cohorts, Post-exposure Prophylaxis, Preemptive Early Treatment, and Pre-exposure prophylaxis

Demographic	N (%) or Median, [IQR]
Participants	2795
Age in years, median [IQR]	40 [34, 49]
Weight in kg, median [IQR]	79 [66, 91]
Women, N (%)	1423 (51.4%)
Ethnicity (all that apply), N (%)	
White or Caucasian	1972 (71.3%)
Black or African American	72 (2.6%)
Asian or South Asian	527 (19.0%)
Hispanic or Latino	132 (4.8%)
Native American or Pacific Islander	36 (1.3%)
Other or Not Stated	68 (2.5%)
Healthcare worker/First Responder, N (%)	2059 (74.4%)
Current smoker, N (%)	80 (2.9%)
No medications listed, N (%)	1825 (66.0%)
No chronic medical conditions, N (%)	1633 (59.0%)

458 459

Safety of Hydroxychloroquine in COVID-19

Table 2. Combined Side Effects Days 1-5 in Post-Exposure Prophylaxis and Early	/
Treatment Cohorts	

	Hydroxychloroquine	Placebo	P-value*
Number randomized	658	654	
Started study medication	576 (87.5%)	563 (86.1%)	0.46
Any side effect (days 1-5)**	231 (40.1%)	101 (17.9%)	<0.001
Side Effects**			
Nausea or upset stomach	146 (25.3%)	53 (9.4%)	<0.001
Diarrhea, abdominal pain, vomiting	131 (22.7%)	35 (6.2%)	<0.001
Irritability, dizziness, vertigo	39 (6.8%)	26 (4.6%)	0.13
Tinnitus	16 (2.8%)	8 (1.4%)	0.15
Headache	15 (2.6%)	8 (1.4%)	0.21
Visual changes	7 (1.2%)	5 (0.9%)	0.77
Skin reaction	10 (1.7%)	4 (0.7%)	0.18
Taste change or dry mouth	3 (0.5%)	3 (0.5%)	>0.99
Allergic reaction	6 (1.0%)	1 (0.2%)	0.12
Hot flashes, night sweats or palpitations	2 (0.3%)	1 (0.2%)	>0.99
Fatigue	1 (0.2%)	1 (0.2%)	>0.99
Panic	0 (0.0%)	1 (0.2%)	0.49
Other	1 (0.2%)	2 (0.4%)	0.62

\*P values calculated via Fisher's Exact test. \*\*Of those who started study medication.

Safety of Hydroxychloroquine in COVID-19

# Table 3. Odds of Side Effects in Post-exposure Prophylaxis and Early TreatmentCohorts.

Group	Odds Ratio of Any Side Effect	95% Confidence Interval	P-value*
Women vs. Men	1.163	0.827-1.637	0.39
Healthcare Worker vs. Not	0.796	0.570-1.111	0.18
Age < 35 compared with 35-50 years	1.055	0.707-1.576	0.79
Age > 50 compared with 35-50 years	0.726	0.457-1.151	0.17
Weight < 64kg compared with 64-87 kg	1.421	0.911- 2.218	0.12
Weight > 87kg compared with 64-87 kg	0.744	0.470-1.179	0.21

\*P value calculated via Chi-Square

Safety of Hydroxychloroquine in COVID-19

Table 4. Side Effects from Pre-exposure Prophylaxis Cohort through June 25,
2020

	Hydroxychloroquine 2x per week	Hydroxychloroquine 1x per week	Placebo	P-value*
Number randomized	495	494	494	
Number with completed Surveys	462	471	469	
Any side effect**	167 (36.2%)	145 (30.8%)	97 (20.7%)	<0.001
Side Effects**				
Nausea or upset stomach	85 (18.4%)	77 (16.3%)	54 (11.5%)	0.04
Diarrhea, abdominal pain, vomiting	75 (16.2%)	56 (11.9%)	30 (6.4%)	<0.001
Arrhythmia, tachycardia, palpitations	8 (1.7%)	8 (1.7%)	11 (2.3%)	0.73
Irritability, dizziness, vertigo	23 (5.0%)	25 (5.3%)	22 (4.7%)	0.92
Tinnitus	6 (1.3%)	10 (2.1%)	4 (0.9%)	0.26
Fatigue	4 (0.9%)	0 (0.0%)	1 (0.2%)	-
Visual changes	4 (0.9%)	7 (1.5%)	3 (0.6%)	0.41
Skin reaction	22 (4.8%)	11 (2.3%)	10 (2.1%)	0.04
Allergic reaction	4 (0.9%)	2 (0.4%)	3 (0.6%)	0.70
Sleep disturbance	6 (1.3%)	8 (1.7%)	4 (0.9%)	0.52
Myalgia	1 (0.2%)	4 (0.8%)	2 (0.4%)	0.38
Arrhythmias	1(0.2%)	0 (0.0%)	1 (0.2%)	-
Other	14 (3.0%)	10 (2.1%)	5 (1.1%)	0.12

\*P values calculated via Fisher's Exact Test comparing hydroxychloroquine (pooled) versus placebo. \*\*Of participants who completed surveys